# L19IL2/TNF in Patients With Basal Cell Carcinoma

Source: https://onco.cc/trials/nct07227870/  
OnCo record `nct07227870` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of L19IL2/L19TNF in basal cell carcinoma, run by Philogen S.p.A., now recruiting.

## Summary

L19IL2/TNF in Patients With Basal Cell Carcinoma is a phase 2 interventional study registered as NCT07227870 by Philogen S.p.A., with 92 participants planned, started 2026-09 and due to reach its primary completion in 2031-02. Interventions recorded: L19IL2/L19TNF.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07227870
- Phase: 2
- Setting: A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.
- Sponsor: Philogen S.p.A.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07227870: https://clinicaltrials.gov/study/NCT07227870

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct07227870.json